VivoSeq
Oncology

Metastatic Urothelial Cancer

0

Pipeline Programs↗

13

Active Trials↗

6

Companies Involved↗

Metastatic Urothelial Cancer is an early-stage landscape with 0 programs across 6 companies. The most active players are Astellas, Roche, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

68/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Astellas logo

Astellas

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalS

Spanish Oncology Genito-Urinary Group

0 programs

PreclinicalN

Nektar Therapeutics

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

42

clinical trials

Completed19 · 45%
Active, not recruiting7 · 17%
Terminated7 · 17%
Recruiting6 · 14%
Withdrawn2 · 5%
Unknown status1 · 2%

Clinical Trials

Trial Activity

42 trials

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
Recruiting·SShanghai Miracogen Inc.·Phase 3·NCT05754853·290 enrolled
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Recruiting·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 3·NCT06592326·460 enrolled
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Recruiting·EEmory University·Phase 1·NCT04878029·32 enrolled
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Recruiting·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 3·NCT06196736·432 enrolled
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Recruiting·BBicycleTx Limited·Phase 2/3·NCT06225596·956 enrolled
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
Recruiting·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 1/2·NCT06079112·100 enrolled
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
Active, not recruiting·Astellas logoAstellas·Phase 3·NCT04223856·886 enrolled
Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03744793·18 enrolled
Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer
Active, not recruiting·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT05219435·66 enrolled
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Active, not recruiting·Roche logoRoche·Phase 2·NCT05645692·204 enrolled
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03237780·72 enrolled
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT05092958·654 enrolled
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
Active, not recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT03036098·1,314 enrolled
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
Completed·Pfizer logoPfizer·Phase 3·NCT02603432·700 enrolled
Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT02567409·87 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)